Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma

Summary

This is a first in human, phase 1, multicenter, open-label study to determine the safety and tolerability of IGM-2644 as a single agent in participants with relapsed and/or refractory MM, for whom standard therapy does not exist, has proven to be ineffective or intolerable, or is considered inappropriate. Dose escalation and dose expansion cohorts will be enrolled to evaluate safety, preliminary efficacy, and further define a RP2D. The total length of the study, from screening of the first participant to the end of the study, is expected to be approximately 60 months.

Timeline

Start

2023-08-29

Primary completion

2024-02-16

Completion

2024-02-16

Outcome

Outcome not reported

Stopped: “Company Decision”

Drugs

Indications